Pfizer Inc. and BioNTech SE said their Covid vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.
A three-dose regimen was 80.3% effective in a preliminary finding based on 10 infections in children ages 6 months through 4 years old, the vaccine partners said in a statement on Monday. A formal analysis will be done once 21 children are infected, as the study was designed, and final efficacy data will be shared when available.
